Mainz Biomed Announces Partnership with Labor Staber to Expand ColoAlert Commercialization in Germany
Labor Staber to actively market and sell ColoAlert to its physician and patient network. BERKELEY, US – MAINZ, Germany – [March 15, 2023] — Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today a partnership with Dr Staber & Kollegen GmbH (Labor […]
Mainz Biomed Launches Number of Educational Events in Germany to Raise Awareness for CRC Screening and Early Detection
Sponsor of Gastro Update 2023, 2-day scientific and training events for gastroenterology professionals Patient Education Day in the City of Mainz, Germany, where the Company is headquartered Germany-based molecular diagnostic specialist to support local colorectal cancer communities BERKELEY, US – MAINZ, Germany – March 8, 2023 — Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), […]
Mainz Biomed Recognizes Colorectal Cancer Awareness Month Throughout “Blue” March 2023
Mainz Biomed to host several events for patients and healthcare professionals in Germany to increase awareness about the importance of early detection of colorectal cancer. BERKELEY, US – MAINZ, Germany – [March 1, 2023] — Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, […]
Mainz Biomed to Appear on ClearThink IR’s Virtual Live Event on Wednesday, March 1, 2023 at 12 Noon ET
Virtual Fireside Chat via Paltalk Platform BERKELEY, US – MAINZ, Germany – February 28, 2023 – Mainz Biomed N.V. (NASDAQ: MYNZ) (“Mainz Biomed ” of the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced that its Chief Financial Officer Bill Caragol will appear on ClearThink IR Virtual Live […]
Mainz Biomed Acquires Entire Intellectual Property Portfolio for its Colorectal Cancer Diagnostic Test Program
Transaction entails executing option agreements to purchase IP portfolio associated with current ColoAlert product and the novel gene expression (mRNA) biomarkers being evaluated in ColoFuture/eAARLY DETECT Studies BERKELEY, US – MAINZ, Germany – February 21, 2023 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection […]
Mainz Biomed Expands European Commercial Footprint and Enters Markets in Spain and UK
Continued roll-out in Europe with onboarding of new lab partners BERKELEY, US – MAINZ, Germany – February 15, 2023 — Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the establishment of commercial partnerships for ColoAlert with Marylebone Laboratory (Marylebone Lab LTD) […]
Mainz Biomed Launches Corporate Health Program in Germany for ColoAlert
Patient Access Initiative Addresses €1 Billion Annual Market in Germany BERKELEY, US – MAINZ, Germany – January 18, 2023 — Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the launch of a corporate health program in Germany for ColoAlert, its highly […]
Mainz Biomed Provides Year-End 2022 Corporate Review
BERKELEY, US – MAINZ, Germany – January 3, 2023 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today a corporate summary for the fiscal year ended December 31, 2022. Key Commercial, Operational and Product Development Highlights Launched U.S.-based eAArly DETECT […]
Mainz Biomed Enrolls First Patient in eAArly DETECT Study Evaluating Integration of Novel mRNA Biomarkers into ColoAlert
— eAArly DETECT Study– Enrollment remains on track to complete in Q1 2023 with results in 1H 2023 Potential to identify advanced adenomas, a type of pre-cancerous polyp often attributed to colorectal cancer (CRC) BERKELEY, US – MAINZ, Germany – December 20, 2022 — Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics […]
Mainz Biomed Announces IRB Approval and Initiation of US Pivotal FDA Clinical Study
ReconAAsense study examining the clinical performance of mRNA and DNA test combined with a fecal immunochemical test for early detection of advanced adenoma and colorectal cancer to enroll 15,000 subjects across the United States, results expected in 2025 Aims to enhance technical profile of the Mainz Biomed test to identify advanced adenomas (AA), a type […]
